COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Osteoradionecrosis and PENTOCLO Protocol: Retrospective Study (OPEN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04097847
Recruitment Status : Completed
First Posted : September 20, 2019
Last Update Posted : November 1, 2019
Information provided by (Responsible Party):
University Hospital, Brest

Brief Summary:
osteoradionecrosis (ORN) affects up to 30% of irradiated patients and can occur up to several decades after stopping treatment. Differents therapeutics exist but there is no consensus concerning the management of the maxillary ORN. The understanding of new pathological mechanisms opens the way to new therapeutic perspectives.

Condition or disease Intervention/treatment
Osteoradionecrosis of Jaw Drug: Pentoxifylline-Tocopherol-Clodronate

Layout table for study information
Study Type : Observational
Actual Enrollment : 96 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Osteoradionecrosis and PENTOCLO Protocol: Retrospective Study.
Actual Study Start Date : June 2, 2017
Actual Primary Completion Date : April 1, 2019
Actual Study Completion Date : April 1, 2019

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: Pentoxifylline-Tocopherol-Clodronate
    the aim of this retrospective study is to analyze from patient records the impact of the PENTOCLO protocol on maxillofacial osteoradionecrosis at Brest Hospital University, France.
    Other Name: Pentoclo

Primary Outcome Measures :
  1. Clinical evolution of the osteoradionecrosis lesion after introducing PENTOCLO protocol [ Time Frame: 2 years ]
    Retrospective study based on recovering patient data from medical records

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
all patients treated at Brest hospital University for ENT cancer and who had cervicofacial radiotherapy, with maxillary and / or mandibular osteoradionecrosis treated with PENTOCLO alone or in combination with other therapies

Inclusion Criteria:

  • Patient over 18 being or having been treated by pentoclo combination for an osteoradionecrosis of the jaw

Exclusion Criteria:

  • Tumoral recidivism
  • Precocious stop of pentoclo

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04097847

Layout table for location information
CHRU de Brest
Brest, France, 29609
Sponsors and Collaborators
University Hospital, Brest
Layout table for additonal information
Responsible Party: University Hospital, Brest Identifier: NCT04097847    
Other Study ID Numbers: OPEN (29BRC17.0115)
First Posted: September 20, 2019    Key Record Dates
Last Update Posted: November 1, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Radiation Injuries
Wounds and Injuries
Clodronic Acid
Vitamin E
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Radiation-Protective Agents
Protective Agents
Physiological Effects of Drugs
Vasodilator Agents
Free Radical Scavengers
Growth Substances
Bone Density Conservation Agents